Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and curr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-06-01
|
| Series: | Medical Sciences |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-3271/5/2/14 |